HYAL4-V1/Chondroitinase (Chase) Drives Gemcitabine Resistance and Predicts Chemotherapy Failure in Patients with Bladder Cancer-Reference-Cited by-同舟云学术

HYAL4-V1/Chondroitinase (Chase) Drives Gemcitabine Resistance and Predicts Chemotherapy Failure in Patients with Bladder Cancer

Published:2021-05-24 Issue:15 Volume:27 Page:4410-4421
ISSN:1078-0432
Container-title:Clinical Cancer Research
language:en
Short-container-title:Clin Cancer Res

Author:

Hasanali Sarrah L.^ORCID,Morera Daley S.^ORCID,Racine Ronny R.,Hennig Martin,Ghosh Santu,Lopez Luis E.,Hupe Marie C.,Escudero Diogo O.,Wang Jiaojiao,Zhu Huabin,Sarcan Semih^ORCID,Azih Ijeoma,Zhou Michael,Jordan Andre R.,Terris Martha K.,Kuczyk Markus A.,Merseburger Axel S.,Lokeshwar Vinata B.

Funder

the NCI

United States Army Medical Research and Development Command

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Metabolic reprogramming based on RNA sequencing of gemcitabine-resistant cells reveals the FASN gene as a therapeutic for bladder cancer;Journal of Translational Medicine;2024-01-13

2. Genome-wide profiling of dysregulated piRNAs and their target genes implicated in oncogenicity of tongue squamous cell carcinoma;Gene;2023-01

3. Intratumoral bacteria are an important “accomplice” in tumor development and metastasis;Biochimica et Biophysica Acta (BBA) - Reviews on Cancer;2023-01

4. Characterization of Hyaluronidase 4 Involved in the Catabolism of Chondroitin Sulfate;Molecules;2022-09-18

5. Alternative splicing in bladder cancer: potential strategies for cancer diagnosis, prognosis, and treatment;WIREs RNA;2022-09-05